MedTrace Logo

DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases

NCT00955617 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-11-02

Study results available
· View outcomes & findings →

Summary

This study is an intra-individual comparison of DOTAREM®-enhanced MRA and GADOVIST®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.

Conditions

  • Peripheral Arterial Disease

Interventions

OTHER

Contrast-enhanced MRA - Imaging examination

Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)

Sponsors & Collaborators

  • Guerbet

    lead INDUSTRY

Principal Investigators

  • Guerbet · Guerbet

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-06-30
Completion
2010-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00955617 on ClinicalTrials.gov